Ciccarelli E, Miola C, Avataneo T, Camanni F, Besser G M, Grossman A
Department of Biomedicine, University of Turin, Italy.
Fertil Steril. 1989 Dec;52(6):930-5. doi: 10.1016/s0015-0282(16)53154-9.
A new long-acting repeatable injectable form of bromocriptine, (Parlodel LAR, Sandoz, Basle, Switzerland) has recently been developed. We studied the clinical, hormonal and radiological changes in six female patients with microprolactinomas and eight (3 female and 5 male) with macroprolactinomas receiving monthly injections of Parlodel LAR 50 to 100 mg for 6 months. Five patients with microadenomas and 4 with macroadenomas had normal prolactin (PRL) levels with Parlodel LAR 50 mg after one (5 patients), two (2 patients), or five (2 patients) injections; two patients with macroadenomas had normal or near normal PRL levels only after 4 monthly injections of 100 mg. Clinical improvement paralleled the changes in serum PRL. A complete normalization of a visual field defect occurred in one patient after 5 months of therapy. Marked shrinkage of the adenoma was shown by magnetic resonance and/or computed tomographical imaging in three patients with macroadenomas after 1 week. Side-effects were mild and usually transient. Parlodel LAR represents a novel treatment of hyperprolactinemic states which is both effective and well tolerated, and appears to be a useful alternative to oral therapy for long-term treatment.
一种新型长效可重复注射的溴隐亭制剂（Parlodel LAR，山德士公司，瑞士巴塞尔）最近已研制出来。我们对6例微泌乳素瘤女性患者和8例（3例女性和5例男性）大泌乳素瘤患者进行了研究，这些患者每月注射50至100毫克Parlodel LAR，持续6个月。5例微腺瘤患者和4例大腺瘤患者在注射1次（5例患者）、2次（2例患者）或5次（2例患者）Parlodel LAR 50毫克后泌乳素（PRL）水平正常；2例大腺瘤患者仅在每月注射4次100毫克后PRL水平才正常或接近正常。临床改善与血清PRL的变化平行。1例患者在治疗5个月后视野缺损完全恢复正常。3例大腺瘤患者在1周后经磁共振和/或计算机断层扫描显示腺瘤明显缩小。副作用轻微且通常为一过性。Parlodel LAR是高泌乳素血症状态的一种新型治疗方法，既有效又耐受性良好，似乎是长期治疗口服疗法的一种有用替代方法。
